OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion

Thanks to our partner:Superpower - https://superpower.comIn episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa's medical school and says the platform will see more than 8 million patients this year and treat more than a million a month, across 400-plus brands from telehealth companies to grocery stores, dating apps, and gyms. He said he thinks GLP-1s will become a default medication the way statins did for cholesterol: he expects 80% of people over 30 could be on them by 2035, and he thinks Andrew Dudum's path to $40-$50 a month cash-pay is directionally right, maybe lower. On peptides he thinks some could be legal to compound before year-end, but not all at once. And he sizes today's gray market at $6 to $8 billion. 00:00 - Sponsor: Superpower01:37 - The Shopify of virtual healthcare04:32 - OpenLoop serving 8M patients this year05:33 - MEDVi 07:08 - OpenLoop's January data breach08:13 - Consumerism in healthcare10:38 - 80% of people over 30 will be on GLP-1s16:22 - Peptides likely this year, but not all at once18:46 - Ready to launch peptides the day FDA allows21:17 - Peptide API from FDA green-listed vendors22:51 - Peptide gray market is $6 to $8 billion27:01 - AI data moatsDisclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.